GSK announced Tuesday that it has dosed the first participant in a Phase 3 trial of its recombinant subunit prefusion RSV vaccine candidate for older adults.
The company began Phase 3 trials for a second RSV candidate (for maternal immunization) in November 2020 and is testing a third RSV shot for infants in ongoing Phase 1/2 studies.
In other news, GSK announced Wednesday that it is increasing its diversity targets for senior…